Director at Avalo Therapeutics (AVTX) exercises 3,166 RSUs into common stock
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Avalo Therapeutics director Mitchell Chan exercised restricted stock units that vested into common shares. On March 28, 2026, 3,166 restricted stock units converted into 3,166 shares of common stock at a conversion price of $0.00 per share.
Following the transaction, Chan directly owned 6,333 shares of Avalo Therapeutics common stock. The restricted stock units convert into common stock on a one-for-one basis and are part of a 9,500-unit grant that vests in three equal annual installments starting March 28, 2025.
Positive
- None.
Negative
- None.
Insider Trade Summary
3,166 shares exercised/converted
Mixed
2 txns
Insider
Chan Mitchell
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Restricted Stock Units | 3,166 | $0.00 | -- |
| Exercise | Common Stock | 3,166 | $0.00 | -- |
Holdings After Transaction:
Restricted Stock Units — 3,167 shares (Direct);
Common Stock — 6,333 shares (Direct)
Footnotes (1)
- Restricted stock units convert into common stock on a one-for-one basis. On August 13, 2024, the Reporting Person was granted 9,500 restricted stock units, vesting 1/3 on March 28, 2025, March 28, 2026, and March 28, 2027, subject to the Reporting Person's continued service on such vesting date.
Key Figures
RSUs exercised: 3,166 units
Common shares received: 3,166 shares
Post-transaction holdings: 6,333 shares
+1 more
4 metrics
RSUs exercised
3,166 units
Restricted stock units converted on March 28, 2026
Common shares received
3,166 shares
One-for-one RSU-to-common stock conversion
Post-transaction holdings
6,333 shares
Common stock directly owned after conversion
RSU grant size
9,500 units
Awarded on August 13, 2024
Key Terms
Restricted Stock Units, derivative security, vest, one-for-one basis
4 terms
Restricted Stock Units financial
"Restricted stock units convert into common stock on a one-for-one basis."
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
derivative security financial
"transaction_code_description: Exercise or conversion of derivative security"
A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.
vest financial
"vesting 1/3 on March 28, 2025, March 28, 2026, and March 28, 2027"
A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.
one-for-one basis financial
"Restricted stock units convert into common stock on a one-for-one basis."
FAQ
What insider transaction did Avalo Therapeutics (AVTX) report for Mitchell Chan?
Avalo Therapeutics reported that director Mitchell Chan exercised 3,166 restricted stock units into 3,166 common shares. The units converted at $0.00 per share, increasing his direct ownership to 6,333 common shares after the transaction.
What was the size and structure of Mitchell Chan’s RSU grant at Avalo Therapeutics (AVTX)?
Mitchell Chan received a grant of 9,500 restricted stock units on August 13, 2024. The award vests in three equal installments on March 28, 2025, March 28, 2026, and March 28, 2027, subject to his continued service with Avalo Therapeutics on each vesting date.
At what price did Mitchell Chan’s Avalo Therapeutics (AVTX) RSUs convert into common stock?
The 3,166 restricted stock units converted into common stock at a price of $0.00 per share. This is typical for equity awards where the value is compensation-based, so Chan did not pay cash to receive the 3,166 newly issued common shares.
Does Mitchell Chan’s Avalo Therapeutics (AVTX) Form 4 show any stock sales?
The Form 4 shows only an exercise or conversion of restricted stock units into 3,166 common shares, with no reported sales. Both transactions are coded “M” for derivative exercise and are classified as acquisitions, increasing his direct common stock holdings.
How do Avalo Therapeutics (AVTX) restricted stock units convert into common stock?
Avalo Therapeutics restricted stock units convert into common stock on a one-for-one basis. In this filing, 3,166 restricted stock units became 3,166 common shares when they vested, consistent with the stated one-for-one conversion rate for this equity award.